Zinaida Alexa

Zinaida Alexa

Auto-generated profile, based on publicly available information

Zinaida Alexa

Department of Internal Medicine, Timofei Mosneaga State Republican Hospital, Chisinau, Republic of Moldova

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Medicine and Pharmacy Reports
Verified
Journal Article
Open access
ETEugen Tcaciuc
Eugen Tcaciuc
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
ZAZinaida Alexa
Zinaida Alexa
ATAngela Tcaciuc
Angela Tcaciuc
DADenis Ardeleanu
Denis Ardeleanu
Gastrointestinal manifestations in COVID-19 have been frequently acknowledged by clinicians and scientists. However, their clinical significance and potential influence on the disease outcome is not entirely elucidated. In this study we aim to evaluate gastrointestinal involvement, both digestive symptoms and liver-related changes in hospitalized COVID-19 patients in correlation to the presence or absence of underlying liver disease and rate of mortality. We performed a retrospective cohort study of COVID-19 patients, consecutively admitted in a hospital from Chisinau, between September 3, 2020 and May 31, 2021. Data on clinical symptoms and laboratory findings were collected from electronic clinical records. The cohort was divided into two groups, with and without pre-existing liver disease. The Fisher exact, Pearson Chi-square tests were used to compare groups. A total of 1835 patients were included, 108 (5.9%) with pre-existing liver disease and 1727 (94.1%) without this comorbidity. Digestive symptoms were reported by 331(18%) of the patients, diarrhea being the most common symptom 11.8% (217) and being encountered more in patients with underlying chronic liver disease. No statistical difference was identified between the groups in regard to other symptoms, comorbidities and rate of mortality. But patients with chronic liver disease had significant (P < 0.001) lower ferritin, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in comparison with the other group. At admission, 341 (19.2%) had increased aspartate aminotransferase level (AST) and 317 (17.8%) alanine aminotransferase. The enzyme abnormalities were predominantly mild and transitory. Abnormal AST level at admission and during follow up, higher ESR, CRP, ferritin, lactate dehydrogenase (LDH) was found to correlate with higher rates of mortality. Digestive implications, especially diarrhea in COVID-19 patients is frequent, but do not appear to be associated with mortality. Elevated liver enzymes during hospitalization, age, high ferritin, CRP, LDH might be interpreted as risk factors for mortality in COVID-19 but further studies are needed to address this topic.

1 April 2024 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
TRTatiana Razlog
Tatiana Razlog
RERussu Eugeniu
Russu Eugeniu
ZAZinaida Alexa
Zinaida Alexa
ECEmil Ceban
Emil Ceban
CGCostina Groza
Costina Groza
LGLiliana Groppa
Liliana Groppa
Introduction. COVID-19 was initially considered a predominantly respiratory infection, with mortality associated with progression of respiratory failure, but currently is recognized as a multisystem disease with a wide range of manifestations. One of the most common complications of COVID-19 is acute kidney injury (AKI), which predominantly evolved to chronic kidney disease (CKD). The objective of the study was to investigate the types of acute kidney injury and their prognostic value in hospitalized patients with COVID-19 with evolution to chronic kidney disease. Material and methods. The study utilized a comprehensive database of patients admitted to general department of COVID-19 at Timofei Moșneaga Republican Clinical Hospital from 2020 to 2022 years (in total 1000 patients). The first part of the study was a retrospective study, focusing on patients with confirmed COVID-19 and lung injury was diagnosed by computer tomography. The second part was a prospective study assessing the prognostic value of inflammatory markers, renal functional status and kidney injury. Results. AKI occurs in 29.6% of patients with COVID-19. The risk of AKI and CKD is higher in patients with more comorbidities, a more severe course of disease, elevated levels of ASAT/ALAT > 1.6 and hematuria at admission, which significantly increases the risk of progression to CKD. Patients with a history of CKD, and who had ASAT > 40 U/L, ASAT/ALAT > 1.6 and hematuria, experience the onset of AKI before hospitalization. Independent negative predictors of hospital-developed AKI include hypertension, Charlson Comorbidity Index > 4 points, respiratory failure, ASAT/ALAT > 1.6, D-dimers > 250 ng/ml, and hematuria. Hospital mortality in patients with COVID-19 was 20.8%, compared to 8.5% in patients without AKI, and this rate increased to 50% when AKI developed (p < 0.001). Conclusions. Patients who developed AKI during admission had a higher incidence of negative outcomes compared to those with AKI prior to admission. Independent predictors of in-hospital mortality in COVID-19 patients were increased serum CRP. Death in hospitalized patients with COVID-19 and AKI was independently associated with factors such as age > 75 years, history of CKD, admission to Intensive Care Unit, leukocytosis, and ASAT/ALAT > 1.6.

18 November 2024 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
FDFelicia Darii
Felicia Darii
SSSilvia Stratulat
Silvia Stratulat
APAngela Peltec
Angela Peltec
ZAZinaida Alexa
Zinaida Alexa
OTOlga Tagadiuc
Olga Tagadiuc
Liver fibrosis represents one of the most pressing problems of steatotic liver disease, as it contributes to disease progression and increases the risk of mortality. Early detection of people with type 2 diabetes and liver fibrosis is essential in disease management, to avoid complications. The study is based on the review of the research articles published during the period 01.01.2007-30.05.2024, in the databases PubMed, ScienceDirect, and Google Academic. From the total number of 280 articles, 27 relevant articles were selected. Non-invasive scores are algorithms that incorporate different clinical variables and biomarkers, increasing the sensitivity and specificity of identifying liver fibrosis. The most commonly used scores are APRI, BARD, NFS, FibroTest, and FIB-4. Recent studies demonstrated that these scores have been validated and can be applied in clinical practice. However, the FIB-4 score exceeds the accuracy of other non-invasive scores and has been recommended by several international societies as a screening method for liver fibrosis in people with type 2 diabetes. Noninvasive scores represent promising, useful, and cost-effective diagnostic methods for the diagnosis of liver fibrosis in people with type 2 diabetes. They provide an assessment of prognosis and the development of effective personalized management strategies, eliminating the risks associated with liver biopsy.